13th Edition - Spring MEDAFFAIRS Leaders Forum

Written by Amanda Pulfer on Thursday 5th March 2020

OPEN VIE (Amanda Pulfer, Strategic Director and Sergio Diaz, Patient Centred Outcomes Consultant) were delighted to speak at the Medical Affairs Leaders Forum yesterday. We explored considerations around early evidence generation in the product development process, with a focus on the importance of collaboration with internal and external stakeholders and the importance of involving patients as peers rather than simply as study subjects. 

One of the key drivers for early evidence generation is that the bench to patient pathway is on ‘fast forward’ in areas of high clinical unmet need and hence value data for payers is required months or years earlier than previously. Pharma should consider including value endpoints in Phase 2/Phase 3 studies or running a RWE evidence generation programme alongside clinical trials to ensure data is available when required.

Pink divider

OPEN VIE is a global, technology enabled, evidence and access consultancy, with a focus on patient centricity. We work with you to understand, demonstrate and communicate value to inspire change

If you would be interested to know how OPEN VIE can help with your real world evidence and market access needs, please contact:

Amanda Pulfer, Strategic Director, OPEN VIE

AmandaPulfer@openvie.com